All In Biotech

Drug Trial Radar · NCT06270433

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder: a Multicentre, Open-label, Parallel-group, Randomised Controlled Trial

Last checked: Nov 20, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

80

Planned (sponsor's estimate)

Start

Feb 19, 2024

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Jiangsu Province Nanjing Brain HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of anhedonia in patients with major depression disorder compared to desvenlafaxine succinate sustained-release tablets, to provide evidence-based basis for clinical rational drug use.

Conditions

  • Anhedonia

Interventions

  • Toludesvenlafaxine hydrochloride sustained-release tabletsDrug

    80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks

  • Desvenlafaxine succinate sustained-release tabletsDrug

    50 mg orally once daily dosing for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Snaith-Hamilton Pleasure Scale (SHAPS) Total ScoreTime frame: Baseline and the end of week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Brian Hospital

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.